TheraPsil’s MDMA-Assisted Psychotherapy
Training Program

On September 25th, TheraPsil announced the launch of a MDMA-Assisted Psychotherapy Training Program (read the full press release here). This groundbreaking training expansion represents a monumental leap forward in our mission to provide safe, legal, and effective therapies for individuals grappling with mental health challenges.

Why This Matters

Our expansion into MDMA-assisted psychotherapy training signifies a new chapter of growth and innovation for TheraPsil. We are broadening our advocacy efforts to encompass both psilocybin and MDMA therapies, furthering our commitment to helping patients in medical need gain legal access to psychedelic-assisted psychotherapy through Health Canada’s SAP program.

The Pilot Phase - Led by Dr. Ingrid Pacey

We are excited to announce that the dates have been set for the first three cohorts of our MDMA program, including the recently launched pilot phase. This program offers a unique opportunity for personal growth and transformation.

After the successful pilot phase, which launched in February 2024, we are excited to offer two additional cohorts for MDMA-Assisted Psychotherapy training:

Cohort 2:
June 3-8, 2024, Vancouver

Cohort 3:
September 30 - October 5, 2024, Vancouver

Leading this program is Dr. Ingrid Pacey, a distinguished TheraPsil trainer known for her pivotal role as the Principal Investigator of the MAPS Phase 2 MDMA trial in Vancouver. Dr. Pacey's extensive expertise underscores our commitment to providing top-tier training.

The pilot phase will be open to practitioners who have successfully completed the didactic portion (up to Unit 10) of TheraPsil’s Fundamentals of Psilocybin-Assisted Psychotherapy training program. We encourage all interested and eligible practitioners to apply and be part of this exciting endeavour as we transition out of the pilot phase.

Entrance Requirements

  1. A medical degree (MD, RN), or a graduate degree (MA, Ph.D.) in psychology, counselling psychology, or a closely related field such as psychiatric social work or psychiatric nursing;
  2. Current good standing as a professional member of a provincial clinical counselling or psychotherapy association having a Code of Ethics and a disciplinary body;

Requirements 1 and 2 above may be relaxed to allow those in the process of completing a graduate clinical degree or professional registration, and credentialed spiritual/pastoral counsellors to attend a seminar in situations where a cohort is short one or two fully qualified clinical entrants prior to delivery.

  • Completion (Units 1-10) of TheraPsil’s Fundamentals of Psilocybin-Assisted Psychotherapy training program;
  • Preference will be given to applicants who already have some personal or professional psychedelic experience and have been onboarded to TheraPsil’s Practitioner Directory.

Introduction

TheraPsil’s fundamental mission is to provide access to psilocybin-assisted and MDMA-assisted psychotherapy for Canadians in medical need. Our primary functions involve patient-rights advocacy, clinical assessment, and connecting patients with qualified and capable therapists for treatment.

TheraPsil recognizes the importance of developing a network of suitably trained and trusted physicians, psychotherapists, and nurses who are equipped to support patients seeking MDMA-assisted treatment. To this end, TheraPsil has developed a psilocybin-assisted and MDMA-assisted psychotherapy training program, which is delivered by contracted experts and organizations in the field.

TheraPsil is dedicated to the highest standard of clinical, academic, and ethical excellence in the realm of psychedelic-assisted treatment. Achieving this requires equitable access for all clinicians to our training program, so that patients seeking treatment have access to a diverse range of therapists. TheraPsil respects and welcomes diversity, and warmly encourages members of ethnic, BIPOC, LGBTQIA2S+, gender, religious, and other underserved or marginalized communities to apply.

Our training goal is that all graduates are fully prepared to safely and effectively guide patients through all aspects of a therapeutic MDMA-assisted psychotherapy experience.

Therapsil's MDMA-Assisted Psychotherapy Training Program

This training program consists of 11 Curriculum Units listed and described below:

  • Trainees begin with a set of pre-readings and video content;
  • Trainees attend a seminar involving face-to-face instruction covering units 1-10;
  • Seminars involve knowledge and skill acquisition, self-reflection, and community building. This will involve a flexible mixture of lectures, large and small group discussions, case studies, and skill-practice sessions;
  • Seminars may involve the use of “guest” expert presenters for certain specialized topics;
  • In-person seminar delivery may be scheduled flexibly according to the needs of cohort members (e.g., one-week intensives, weekly or bi-weekly sessions stretching over several months);
  • Maximum cohort size: 20 members;
  • Trainees will have the opportunity to deliver feedback to the trainers throughout the program concerning both content and delivery methods;
  • Total Program Hours:
    In-person Seminar: 24
    Readings/Videos: 48
    Experiential (Unit 10): 31
    Supervision (Unit 11): 10
    Total 113

Graduation Requirements

  • Completion of in-person training seminar (Units 1-9), full attendance is required;
  • Certification of completion of readings and videos;
  • Personal MDMA-assisted psychotherapy experience (Unit 10)
  • Clinical Supervision (Unit 11);
  • Documentation of a minimum of five years of experience as a full-time mental health clinician. (A psychiatric residency counts towards this requirement)
  • At the conclusion of training, trainees will meet individually (in-person or via Zoom) with their principal trainer for a final, individualized assessment session involving all aspects of trainee learning. Trainees assessed as ready for practice will be awarded a Certificate of Completion of TheraPsil’s MDMA-Assisted Psychotherapy Training Program.

Certificates & Professional Designations

A qualified healthcare professional accepted into this program will be a prequalified TheraPsil Affiliate or Associate by having completed our Units 1-10 of TheraPsil’s Fundamentals of Psilocybin-Assisted Psychotherapy Training program.

TheraPsil trainees who have fully attended the 24-hour seminar, and certified that they have completed all required readings and videos may receive (upon request) a Certificate of Completion for 72 hours of didactic instruction in TheraPsil’s MDMA-Assisted Psychotherapy Training Program. To certify that MDMA didactic training is complete, email support@therapsil.ca with a signed and completed pre-reading list.

Trainees who have completed up to Unit 10 may be granted the status of Provisional Associate with MDMA-Assisted Psychotherapy Training for 103 hours of credit by their trainer as they work towards their Unit 11 Supervision requirement. Provisional Associate status allows the trainee’s name to be placed on TheraPsil’s Practitioner Directory to accept patient referrals, and to function as a primary therapist on the condition that they agree to actively pursue completion of their Unit 11 supervision requirement.

Trainees are considered full graduates from this program when they have completed all 11 training units. Graduate psychotherapists will be awarded a Certificate of Completion for 113 hours of training in MDMA-Assisted Psychotherapy. This certificate identifies the graduate as a TheraPsil Psychotherapy Associate with MDMA-Assisted Psychotherapy Training, and their name will be entered into TheraPsil’s Directory of graduate clinicians. This register is made available to prospective patients seeking treatment.

Nurses and social workers without psychotherapy experience who seek to be co-sitters, and who have completed Units 1-10, will be awarded a Certificate of Completion for 103 hours of training that identifies them as TheraPsil-Affiliated Co-Sitters with MDMA-Assisted Psychotherapy Training.

Graduate MDs and Nurse Practitioners without psychotherapy experience who complete Units 1-10 will be awarded a Certificate of Completion for 103 hours in assessment for MDMA-Assisted Psychotherapy. This certificate identifies them as TheraPsil Medical Associates, and their names will be entered into TheraPsil’s Directory of Medical Associates. This directory is made available to prospective patients seeking assessment or application for MDMA-assisted psychotherapy.

Upon completion of the training program, trainees will receive ongoing support from TheraPsil’s Community of Care and Practice, with opportunities to engage in supplementary education focused on emerging research and best clinical practices.

TheraPsil's Curriculum